AbbVie Targets Post Humira Growth With Cell Therapy And RINVOQ Expansion [Yahoo! Finance]
AbbVie Inc. (ABBV)
Last abbvie inc. earnings: 5/1 07:43 am
Check Earnings Report
US:NYSE Investor Relations:
investors.abbvie.com/investor-overview
Company Research
Source: Yahoo! Finance
AbbVie (NYSE:ABBV) has agreed to acquire Capstan Therapeutics to expand its work in in vivo CAR-T cell therapy. The company has also submitted upadacitinib (RINVOQ) for FDA and EMA review as a potential treatment for vitiligo. For you as an investor, these updates relate to AbbVie's strategy after Humira's patent expiry to position itself as a broad-based biopharma company with exposure to complex immunology and oncology treatments. The Capstan deal adds a new cell therapy platform, while the RINVOQ filings in vitiligo extend an existing drug into a new disease area with limited systemic treatment options today. Together, they illustrate AbbVie using both acquisitions and label expansion to shape its future product mix. If you are tracking NYSE:ABBV, these moves may be worth watching as potential contributors to the company's longer term product pipeline and revenue diversity. Stay updated on the most important news stories for AbbVie by adding it to your watchlist or portfol
Show less
Read more
Impact Snapshot
Event Time:
ABBV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABBV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABBV alerts
High impacting AbbVie Inc. news events
Weekly update
A roundup of the hottest topics
ABBV
News
- AbbVie Inc. (ABBV) Achieves Record Net Sales on Diversified Growth Platform [Yahoo! Finance]Yahoo! Finance
- AbbVie (NYSE:ABBV) was upgraded by analysts at UBS Group AG to a "hold" rating.MarketBeat
- AbbVie sues US health agency over Botox price controls [Yahoo! Finance Canada]Yahoo! Finance Canada
- AbbVie (NYSE:ABBV) had its "market perform" rating reaffirmed by analysts at Sanford C. Bernstein.MarketBeat
- AbbVie (NYSE:ABBV) was given a new $230.00 price target on by analysts at UBS Group AG.MarketBeat
ABBV
Earnings
- 2/4/26 - Miss
ABBV
Sec Filings
- 2/4/26 - Form 8-K
- 1/7/26 - Form 8-K
- 1/5/26 - Form 4
- ABBV's page on the SEC website